BioLine Rx Analyst Ratings
BioLine Rx Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 1093.18% | HC Wainwright & Co. | $19 → $21 | Maintains | Buy |
| 08/31/2023 | 979.55% | HC Wainwright & Co. | → $19 | Reiterates | Buy → Buy |
| 05/25/2023 | 127.27% | Oppenheimer | → $4 | Reiterates | → Outperform |
| 02/23/2021 | 979.55% | HC Wainwright & Co. | $22 → $19 | Maintains | Buy |
| 12/16/2020 | 1150% | HC Wainwright & Co. | $18 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023/09/15 | 1093.18% | HC Wainwright公司 | $19→$21 | 維護 | 買 |
| 2023年08月31日 | 979.55% | HC Wainwright公司 | →$19 | 重申 | 購買→購買 |
| 2023年05月25日 | 127.27% | 奧本海默 | →$4 | 重申 | →跑贏大盤 |
| 02/23/2021 | 979.55% | HC Wainwright公司 | $22→$19 | 維護 | 買 |
| 12/16/2020 | 1150% | HC Wainwright公司 | $18→$22 | 維護 | 買 |
What is the target price for BioLine Rx (BLRX)?
Bioline Rx(BLRX)的目標價格是多少？
The latest price target for BioLine Rx (NASDAQ: BLRX) was reported by HC Wainwright & Co. on September 15, 2023. The analyst firm set a price target for $21.00 expecting BLRX to rise to within 12 months (a possible 1093.18% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年9月15日報道了Bioline Rx(納斯達克代碼：BLRX)的最新目標價。這家分析公司將目標價定為21美元，預計BLRX將在12個月內上漲至(可能上漲1093.18%)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for BioLine Rx (BLRX)?
Bioline Rx(BLRX)的最新分析師評級是多少？
The latest analyst rating for BioLine Rx (NASDAQ: BLRX) was provided by HC Wainwright & Co., and BioLine Rx maintained their buy rating.
分析師對Bioline Rx(納斯達克代碼：BLRX)的最新評級由HC Wainwright&Co.提供，Bioline Rx維持買入評級。
When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?
Bioline Rx(BLRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Bioline Rx的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Bioline Rx的上一次評級是在2023年9月15日提交的，所以你應該預計下一次評級將在2024年9月15日左右提供。
Is the Analyst Rating BioLine Rx (BLRX) correct?
分析師對Bioline Rx(BLRX)的評級正確嗎？
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a maintained with a price target of $19.00 to $21.00. The current price BioLine Rx (BLRX) is trading at is $1.76, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Bioline Rx(BLRX)評級維持不變，目標價在19.00美元至21.00美元之間。Bioline Rx(BLRX)目前的交易價格為1.76美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。